Welcome to the Ortlund Lab
We use sophisticated structural biology techniques such as x-ray crystallography and mass spectrometry coupled with an array of biochemical techniques to gain a molecular level understanding of transcriptional signaling - with a particular focus on lipid mediated signaling and transport. We currently pursue structural and biochemical studies of human nuclear receptors, which are lipid regulated transcription factors that play central roles in development, cancer, stress and metabolism. We have also made seminal contributions to the field of molecular evolution using nuclear receptors as a model system to study how tight molecular partnerships evolve.
Lab News
Biolocity Award
Congratulations to Eric Ortlund, PhD, Professor and Vice Chair of Biochemistry at Emory School of Medicine, and John Calvert, PhD, Associate Professor of Surgery and Biochemistry at Emory School of Medicine, for their recent Biolocity Award, “Targeting HpEF with Urearetics”.
Therapeutic Advancement Award
Congratulations to Eric Ortlund, PhD, Professor and Vice Chair of Biochemistry, on earning the Therapeutic Advancement Award from the Emory Center for New Medicines.
"Deal of the Year" Award
New Publication in "JBC"
June 2023: Congratulations to Lee Cato, Emma D’Agostino, Racheal Spurlin, Sarah Abraham, and Eric Ortlund on their publication, "Comparison of Activity, Structure, and Dynamics of SF-1 and LRH-1 Complexed with Small Molecule Modulators," in the Journal of Biological Chemistry, June 2023.
New Publication in "Nature Communications"
June 2023: Congratulations to Sam Druzak, Suzanne Mays, Mireille El-Bejjani, Kristal Maner-Smith, Thomas Bowen, Lee Cato, Matt Tillman, and Eric Ortlund on their recent publication, "Ligand dependent interaction between PC-TP and PPARδ mitigates diet-induced hepatic steatosis in male mice," in Nature Communications, June 2023.
New Publication in "Structure"
May 2023: The Ortlund Lab shows how #COVID variants can escape immune detection with their publication, "Molecular basis of SARS-CoV-2 Omicron variant evasion from shared neutralizing antibody response," in Structure.
